Criteria for Prior Authorization — Ulcerative Colitis Agents
Customize your policy alerts
Sign up for all Kansas Department of Health and Environment policy alerts
Know when Kansas Department of Health and Environment releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements, initial and renewal clinical criteria, dosing limits, and therapeutic monitoring requirements for prescription agents used to treat ulcerative colitis for Kansas Department of Health and Environment members.
References and prescribing information entries were updated through 2025, including new/updated product labels cited (e.g., Humira, Remicade, Xeljanz, Rinvoq, Stelara, Zeposia).
2025 ACG guideline update is cited as a reference (ACG Clinical Guideline Update: Ulcerative Colitis in Adults).
Coverage Criteria for Ulcerative Colitis Agents
Initial Therapy
Covered when ALL of the following are met for initial PA:
Induction of remission (ONE of)
- Had an adequate trial (at least 4 weeks) of an oral systemic corticosteroid equivalent to 40–60 mg/day prednisone with a planned taper.
- Had an inadequate response within 3–5 days of an intravenous corticosteroid equivalent to 60 mg/day methylprednisolone or 100 mg hydrocortisone 3–4 times per day.
Continuation / Renewal Therapy
Covered when ALL of the following are met for renewal PA:
Concomitant therapy restriction
Concurrency restriction:
Use of tofacitinib in combination with other biologic therapies for ulcerative colitis or with potent immunosuppressants (for example, azathioprine and cyclosporine) is not recommended due to safety concerns described in the product labeling and policy notes. The drug label and FDA communications identify increased risks (including serious heart-related events, cancer, blood clots, and death) that restrict the population appropriate for JAK inhibitor use; the labeling also limits JAK inhibitor use to patients who have not responded to or cannot tolerate one or more TNF inhibitors.
When prescribing or authorizing tofacitinib, ensure dosing and indication match the product labeling and that the patient meets required prior‑authorization prerequisites (including documentation of prior therapies and induction/maintenance criteria). If alternative dosing is proposed, therapeutic drug monitoring evidence should be provided to support the request.
Continuation of therapy without objective evidence of benefit by the policy’s defined timepoints may be considered non‑beneficial and subject to discontinuation. Examples called out in the policy include discontinuing vedolizumab if there is no evidence of therapeutic benefit by week 14, and discontinuing tofacitinib if adequate therapeutic benefit is not achieved by 16 weeks.
For renewal authorization, prescribers must submit objective measures of response (for example, endoscopic mucosal healing or fecal calprotectin at or below the policy threshold) or a clear rationale that other pharmacologic and non‑pharmacologic options have been exhausted; requests lacking such documentation risk denial.
Covered Agents and Measurement Definitions
| Adalimumab (Humira®, Abrilada™, Amjevita®, Cyltezo®, Hadlima™, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, Yusimry®) | Adalimumab (Humira and biosimilars) |
| Etrasimod (Velsipity®) | Etrasimod |
| Golimumab (Simponi®) | Golimumab |
| Guselkumab (Tremfya®) | Guselkumab |
| Infliximab (Remicade®, Renflexis®, Inflectra®, Avsola®) | Infliximab |
| Infliximab-dyyb (Zymfentra®) | Infliximab-dyyb |
| Mirikizumab-mrkz (Omvoh®) | Mirikizumab-mrkz |
| Ozanimod (Zeposia®) | Ozanimod |
| Risankizumab-rzaa (Skyrizi®) | Risankizumab-rzaa |
| Tofacitinib (Xeljanz®, Xeljanz® XR) | Tofacitinib |
Prior Authorization, Documentation, and Operational Requirements
Prior authorization required for all listed UC agents
Prior authorization is required for all listed ulcerative colitis agents and all current and future dose forms; medication-specific criteria (indication, age, dose) are defined in Table 1.
Induction and maintenance prerequisites
For induction, the patient must have had an adequate trial (at least 4 weeks) of an oral systemic corticosteroid equivalent to 40–60 mg/day prednisone with planned taper OR an inadequate response within 3–5 days of an IV corticosteroid (methylprednisolone 60 mg/day or hydrocortisone 100 mg 3–4 times daily). For maintenance, the patient must have failed to achieve mucosal healing within 4 months or relapsed despite continuous conventional therapy; for tofacitinib and upadacitinib specifically, the patient must have had an adequate trial (at least 6–8 weeks) of or a contraindication to a TNF blocker.
- Induction options: ≥4 weeks oral systemic corticosteroid (40–60 mg/day prednisone equivalent) with taper, or inadequate response to IV corticosteroid within 3–5 days.
- Maintenance: failure to achieve mucosal healing within 4 months or relapse despite conventional therapy.
- Tofacitinib/upadacitinib: adequate trial (6–8 weeks) of or contraindication to a TNF blocker is required.
Required documentation and monitoring (including TDM)
Prescriber must submit documentation to support alternative dosing or dose optimization (e.g., therapeutic drug monitoring such as drug and antibody levels) and provide baseline assessments (at least one: fecal calprotectin >150 μg/g or endoscopy) and, at renewal, objective response measures (endoscopic mucosal healing or fecal calprotectin ≤150 μg/g) or rationale that other options are exhausted.
- Submit drug and antibody levels or other TDM evidence to justify dosing outside Table 1 limits.
- Provide baseline assessment: at least one of fecal calprotectin >150 μg/g or endoscopic assessment.
- For renewal, provide endoscopic Mayo subscore ≤1 or fecal calprotectin ≤150 μg/g, or documentation that other options are exhausted.
Risk of denial if PA criteria not met
Requests that do not meet all general initial or renewal PA criteria — including indication/age/dose limits, required prior/conventional therapy or induction criteria, prescriber requirement, and required therapeutic monitoring/documentation — risk denial.
Clinical Background
Ulcerative colitis is managed with a stepwise treatment approach. Initial control of active disease commonly uses systemic corticosteroids for induction, followed by conventional immunomodulators and targeted therapies (biologic agents and JAK inhibitors) for maintenance and steroid‑sparing control. Therapeutic drug monitoring (trough concentrations) and objective assessments of mucosal healing (endoscopic Mayo subscore and fecal calprotectin) are used to guide treatment choice and dosing optimization.
Prior authorization is required for the listed ulcerative colitis agents. For induction, the policy requires evidence of an adequate trial of systemic oral corticosteroid (approximately 4 weeks) or failure of IV corticosteroids; for certain JAK inhibitors (tofacitinib, upadacitinib) an adequate trial (approximately 6–8 weeks) of or contraindication to a TNF blocker is required before initiation. Renewal criteria require documentation of objective response (mucosal healing defined as endoscopic Mayo subscore ≤ 1 or fecal calprotectin ≤ 150 μg/g) or documentation that other options are exhausted.
The policy also includes safety and monitoring provisions: vedolizumab should be discontinued if no benefit is seen by week 14, and tofacitinib should be discontinued after 16 weeks if adequate therapeutic benefit is not achieved. Prescribers must provide baseline and follow‑up objective data (endoscopy or fecal calprotectin) and therapeutic drug monitoring where applicable to support dosing decisions and renewals.
Key Clinical Definitions and Monitoring Targets
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.